Disposition of 35280 shares by Tracy Smith of Optical Cable at 3.61 subject to Rule 16b-3

OCUL Stock  USD 9.75  0.66  7.26%   
About 54% of Ocular Therapeutix's investor base is interested to short. The analysis of overall sentiment of trading Ocular Therapeutix stock suggests that many investors are impartial at this time. Ocular Therapeutix's investing sentiment shows overall attitude of investors towards Ocular Therapeutix.
  
Filed transaction by Optical Cable Officer Svp And Cfo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 35280 common stock at 3.61 of Optical Cable by Tracy Smith on 2nd of July 2024. This event was filed by Optical Cable with SEC on 2019-01-31. Statement of changes in beneficial ownership - SEC Form 4. Tracy Smith currently serves as cfo, sr. vp and corporate secretary of Optical Cable

Cash Flow Correlation

Ocular Therapeutix's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Ocular Therapeutix's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Ocular Therapeutix Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Ocular Therapeutix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Ocular Therapeutix Fundamental Analysis

We analyze Ocular Therapeutix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocular Therapeutix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocular Therapeutix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Sales

Price To Sales Comparative Analysis

Ocular Therapeutix is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Ocular Therapeutix Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ocular Therapeutix stock to make a market-neutral strategy. Peer analysis of Ocular Therapeutix could also be used in its relative valuation, which is a method of valuing Ocular Therapeutix by comparing valuation metrics with similar companies.

Peers

Ocular Therapeutix Related Equities

CTMXCytomX Therapeutics   6.25   
0%
92.0%
XFORX4 Pharmaceuticals   2.94   
0%
43.0%
ASMBAssembly Biosciences   2.63   
0%
38.0%
TERNTerns Pharmaceuticals   1.55   
0%
22.0%
HOOKHookipa Pharma   1.31   
0%
19.0%
ACHLAchilles Therapeutics   0.94   
0%
13.0%
DAWNDay One   0.89   
0%
13.0%
MREOMereo BioPharma   0.59   
0%
8.0%
INZYInozyme Pharma   0.38   
0%
5.0%
SPROSpero Therapeutics   1.74   
25.0%
0%
PDSBPDS Biotechnology   2.76   
40.0%
0%
AMLXAmylyx Pharmaceuticals   3.71   
54.0%
0%
ABOSAcumen Pharmaceuticals   6.78   
100.0%
0%
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
Check out Ocular Therapeutix Hype Analysis, Ocular Therapeutix Correlation and Ocular Therapeutix Performance.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.29)
Revenue Per Share
0.529
Quarterly Revenue Growth
0.083
Return On Assets
(0.22)
Return On Equity
(0.73)
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.